What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
Paul J. Thuluvath mainly investigates Internal medicine, Liver transplantation, Gastroenterology, Surgery and Transplantation.
The concepts of his Internal medicine study are interwoven with issues in Diabetes mellitus and Endocrinology.
His Liver transplantation study integrates concerns from other disciplines, such as Bilirubin, Proportional hazards model and Sepsis.
His studies in Gastroenterology integrate themes in fields like Daclatasvir, Ribavirin, Immunology and Primary sclerosing cholangitis, Disease.
His study explores the link between Surgery and topics such as Hazard ratio that cross with problems in Independent predictor, Cohort study, Orthotopic liver transplantation and Cause of death.
His research in Transplantation intersects with topics in Liver disease and Hepatocellular carcinoma.
His most cited work include:
- Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection (955 citations)
- All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study (485 citations)
- Liver Transplantation in the United States, 1999–2008 (470 citations)
What are the main themes of his work throughout his whole career to date?
Paul J. Thuluvath mainly focuses on Internal medicine, Gastroenterology, Liver transplantation, Cirrhosis and Surgery.
His work in the fields of Internal medicine, such as Liver disease, Hepatology, Hepatitis C and Hepatocellular carcinoma, intersects with other areas such as In patient.
His research investigates the connection between Gastroenterology and topics such as Ribavirin that intersect with problems in Regimen.
His work focuses on many connections between Liver transplantation and other disciplines, such as Proportional hazards model, that overlap with his field of interest in Confounding.
His Cirrhosis study incorporates themes from Prospective cohort study, Dialysis and Cohort.
His Surgery study combines topics from a wide range of disciplines, such as Odds ratio and Hazard ratio.
He most often published in these fields:
- Internal medicine (71.37%)
- Gastroenterology (46.37%)
- Liver transplantation (33.47%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (71.37%)
- Cirrhosis (27.82%)
- Gastroenterology (46.37%)
In recent papers he was focusing on the following fields of study:
Paul J. Thuluvath focuses on Internal medicine, Cirrhosis, Gastroenterology, Cohort and Liver disease.
Paul J. Thuluvath undertakes multidisciplinary investigations into Internal medicine and In patient in his work.
His Cirrhosis research integrates issues from Dialysis, Cohort study, Emergency medicine and Intensive care medicine.
His work carried out in the field of Gastroenterology brings together such families of science as Acute kidney injury and Patient survival.
His work in Cohort tackles topics such as Hepatic encephalopathy which are related to areas like Hepatology, Metabolite and Area under the curve.
Paul J. Thuluvath combines subjects such as Liver function, Liver transplantation, Model for End-Stage Liver Disease, Steatohepatitis and Severity of illness with his study of Liver disease.
Between 2018 and 2021, his most popular works were:
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension (51 citations)
- Impact of Chronic Kidney Disease on Outcomes in Cirrhosis (14 citations)
- Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared With Cryptogenic, Alcoholic, or AIH Cirrhosis. (14 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Cancer
Cirrhosis, Internal medicine, Gastroenterology, Portal hypertension and Liver disease are his primary areas of study.
His study looks at the relationship between Cirrhosis and topics such as Cohort study, which overlap with Pharmacotherapy, Lactulose and Cohort.
Paul J. Thuluvath conducts interdisciplinary study in the fields of Internal medicine and Sleep deprivation through his research.
Gastroenterology connects with themes related to Dialysis in his study.
In his study, Randomized controlled trial, Nonalcoholic fatty liver disease, Esophageal varices and Varices is inextricably linked to Placebo, which falls within the broad field of Portal hypertension.
His research integrates issues of Liver transplantation, Kidney disease, Renal function, Creatinine and Acute kidney injury in his study of Liver disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
